Dexcom [DXCM] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Dexcom Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Dexcom Inc. wins in 7 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Dexcom Inc. Abbott Laboratories Better
P/E Ratio (TTM) 30.03 25.97 Abbott Laboratories
Price-to-Book Ratio 8.63 3.09 Abbott Laboratories
Debt-to-Equity Ratio 50.85 26.79 Abbott Laboratories
PEG Ratio 0.39 -1.41 Dexcom Inc.
EV/EBITDA 19.85 13.74 Abbott Laboratories
Profit Margin (TTM) 17.94% 13.90% Dexcom Inc.
Operating Margin (TTM) 25.64% 16.50% Dexcom Inc.
EBITDA Margin (TTM) 25.64% 16.50% Dexcom Inc.
Return on Equity 34.50% 12.36% Dexcom Inc.
Return on Assets (TTM) 8.89% 7.52% Dexcom Inc.
Free Cash Flow (TTM) $1.08B $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -8.07% -34.98% Dexcom Inc.
Price-to-Sales Ratio (TTM) 5.10 3.57 Abbott Laboratories
Enterprise Value $23.09B $166.96B Abbott Laboratories
EV/Revenue Ratio 4.95 3.70 Abbott Laboratories
Gross Profit Margin (TTM) 62.93% N/A N/A
Revenue per Share (TTM) $12 $26 Abbott Laboratories
Earnings per Share (Diluted) $2.05 $3.57 Abbott Laboratories
Beta (Stock Volatility) 1.56 0.78 Abbott Laboratories
Short % of Float 4.93% 1.53% Abbott Laboratories

Dexcom Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

DXCM
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Dexcom Inc.-1.53%-3.13%20.43%11.88%12.92%11.54%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Dexcom Inc.-8.07%-42.07%-27.92%315.26%2,149.85%2,129.88%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Dexcom Inc. vs Abbott Laboratories

MetricDXCMABT
Market Information
Market Cap i$23.76B$160.70B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i4,652,60413,495,583
90 Day Avg. Volume i4,100,84812,934,461
Last Close$74.22$88.67
52 Week Range$54.11 - $89.98$81.97 - $139.06
% from 52W High-17.52%-36.24%
All-Time High$164.86 (Nov 15, 2021)$142.60 (Dec 27, 2021)
% from All-Time High-54.98%-37.82%
Growth Metrics
Quarterly Revenue Growth0.13%0.08%
Quarterly Earnings Growth0.76%-0.19%
Financial Health
Profit Margin (TTM) i0.18%0.14%
Operating Margin (TTM) i0.26%0.17%
Return on Equity (TTM) i0.35%0.12%
Debt to Equity (MRQ) i50.8526.79
Cash & Liquidity
Book Value per Share (MRQ)$7.14$30.02
Cash per Share (MRQ)$5.19$5.14
Operating Cash Flow (TTM) i$1.44B$10.80B
Levered Free Cash Flow (TTM) i$719.54M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Dexcom Inc. vs Abbott Laboratories

MetricDXCM (Apr 26, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i30.0325.97
Forward P/E i20.5915.29
PEG Ratio i0.39-1.41
Price to Sales (TTM) i5.103.57
Price to Book (MRQ) i8.633.09
Market Capitalization
Market Capitalization i$23.76B$160.70B
Enterprise Value i$23.09B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i4.953.70
Enterprise to EBITDA i19.8513.74
Risk & Other Metrics
Beta i1.560.78
Book Value per Share (MRQ) i$7.14$30.02

Financial Statements Comparison: Dexcom Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricDXCM (2025)ABT (2025)
Revenue/Sales i4.66B44.33B
Cost of Goods Sold i1.86B19.32B
COGS % of Revenue i39.9%43.6%
Gross Profit i2.80B25.01B
Gross Margin i60.1%56.4%
Research & Development i599.10M2.94B
Operating Income (EBIT) i911.80M8.05B
Operating Margin i19.6%18.2%
EBITDA i1.36B12.03B
EBITDA Margin i29.1%27.1%
Pre-Tax Income i1.09B8.47B
Pre-Tax Income % of Revenue i23.3%19.1%
Income Tax i252.10M1.94B
Income Tax % of Revenue i5.4%4.4%
Net Income (Profit) i836.30M6.52B
Profit Margin i17.9%14.7%

Balance Sheet & Liquidity Metrics

MetricDXCM (2025)ABT (2025)
Cash & Equivalents i917.70M8.52B
Total Current Assets i4.03B26.00B
Total Current Assets % of Revenue i86.5%58.6%
Total Current Liabilities i2.14B16.50B
Total Current Liabilities % of Revenue i46.0%37.2%
Long-Term Debt i1.37B10.83B
Long-Term Debt % of Revenue i29.3%24.4%
Total Shareholders Equity i2.75B52.77B
Retained Earnings i2.43B49.78B
Retained Earnings % of Revenue i52.2%112.3%
Property, Plant & Equipment i77.40M17.57B

Cash Flow Statement Comparison

MetricDXCM (2025)ABT (2025)
Operating Cash Flow i1.48B10.80B
Operating Cash Flow % of Revenue i31.7%24.4%
Capital Expenditures i-363.50M-2.17B
Free Cash Flow i1.08B7.40B
FCF Margin i23.1%16.7%
Debt Repayment i-1.21B-1.50B
Common Stock Repurchase i-500.00M-893.00M

Short Interest & Institutional Ownership Analysis

MetricDXCMABT
Shares Short i14.72M23.83M
Short Ratio i3.771.93
Short % of Float i4.93%1.53%
Shares Outstanding i384.80M1.74B
Float Shares i382.94M1.73B
% Held by Insiders i0.28%0.54%
% Held by Institutions i101.50%82.23%
% Held by Public i-1.78%17.23%

Dividend Analysis & Yield Comparison: Dexcom Inc. vs Abbott Laboratories

MetricDXCMABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026